Gerson and Barbara Bass Bakar Distinguished Professorship in Cancer Research, UCSF
Member, UCSF Biomedical Sciences Graduate Program (BMS) and Herbert Boyer Program in Biological Sciences (PIBS)
Co-Leader, Cell Cycling and Signaling Program, UCSF Helen Diller Family Comprehensive Cancer Center
| CONTACT | |
|
gevan@cc.ucsf.edu Box 0502, UCSF; San Francisco, CA 94143-0502 |
additional websites: |
| EDUCATION | |
|
University of Oxford, England, M.A., 1973-77, Biochemistry
|
|
| PROFESSIONAL EXPERIENCE | |
|
1982-84 |
Post-doctoral Research fellow, Laboratory of Prof. J. Michael Bishop, Department of Microbiology and Immunology, University of California, San Francisco, USA |
|
1984-88 |
Laboratory Head, Ludwig Institute for Cancer Research, Cambridge, UK |
|
1988-99 |
Principal Scientist, Imperial Cancer Research Fund, London, UK |
|
1996-99 |
Royal Society Napier Professor of Cancer Research, University College, London, UK |
|
1999-present |
Gerson and Barbara Bass Bakar Distinguished Professor of Cancer Research, Cancer Research Institute and Dept of Molecular and Cellular Pathology, UCSF |
| HONORS & AWARDS | |
|
Gibb Prize for Biochemistry, University of Oxford, UK |
|
|
Max Perutz Prize, MRC LMB Cambridge, UK |
|
|
Research Fellowship, Downing College, Cambridge, UK |
|
|
Pfizer Prize in Biology |
|
|
Napier Research Professor of the Royal Society |
|
|
European Molecular Biology Organization |
|
|
Joseph Steiner Prize in Cancer Research (Swiss Oncological Society) |
|
|
European Life Sciences Organization Founder Member |
|
|
Fellow, Academy of Medical Sciences UK |
|
|
Fellow of the Royal Society |
|
|
Brain Tumor Society Neal P. Levitan Chair of Research |
|
| SELECTED PUBLICATIONS | |
|
Max and c-Myc/Max DNA binding activities in cell extracts. Littlewood, T., Amati, B., Land, H., and Evan, G. Oncogene 7, 1783-1792 (1992). |
|
|
Induction of apoptosis in fibroblasts by c-myc protein. Evan, G., Wyllie, A., Gilbert, C., Littlewood, T., Land, H., Brooks, M., Waters, C., Penn, L., and Hancock, D. Cell 63, 119-125 (1992). |
|
|
c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. Harrington, E. A., Bennett, M. R., Fanidi, A., and Evan, G. I. EMBO J 13, 3286-3295 (1994). |
|
|
A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Littlewood, T., Hancock, D., Danielian, P., Parker, M., and Evan, G. Nuc Acids Res 23, 1686-1690 (1995). |
|
|
Suppression of c-Myc-induced apoptosis by Ras signalling through PI 3-kinase and PKB. Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffer, P., and Evan, G. Nature 385, 544-548 (1997). |
|
|
Identification of a Drosophila melanogaster ICE/CED-3-related protease, drICE. Fraser, A., and Evan, G. EMBO J 16, 2805-2813 (1997). |
|
|
Inhibition of Ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak. McCarthy, N., Whyte, M., Gilbert, C., and Evan, G. J Cell Biol 136, 215-227 (1997). |
|
|
drICE is an essential caspase required for apoptotic activity in Drosophila cells. Fraser, A., McCarthy, N., and Evan, G. EMBO J 16, 6192-6199 (1997). |
|
|
Requirement for the CD95 Receptor-Ligand Pathway in c-Myc Induced Apoptosis. Hueber, A.-O., Zärnig, M., Lyon, D., Suda, T., Nagata, S., and Evan, G. Science 278, 1305-1309 (1997). |
|
|
p53-dependent impairment of T-cell proliferation in FADD dominant-negative transgenic mice. Zärnig, M., Hueber, A.-O., and Evan, G. Curr Biol 8, 467-470 (1998). |
|
|
A matter of life and cell death. Evan, G., and Littlewood, T. Science 281, 1317-22 (1998). |
|
|
c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Juin, P., Hueber, A. O., Littlewood, T., and Evan, G. Genes Dev 13, 1367-81 (1999). |
|
|
Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Pelengaris, S., Littlewood, T., Khan, M., Elia, G., and Evan, G. Mol Cell 3, 565-77 (1999). |
|
|
The Drosophila caspase DRONC is regulated by DIAP1. Meier, P., Silke, J., Leevers, S., and Evan, G. EMBO J 19, 598-611 (2000). |
|
|
The co-ordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Goldstein, J., Waterhouse, N., Juin, P., Evan, G., and Green, D. Nature Cell Biol 2, 156-162 (2000). |
|
|
Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER mice. Blyth, K., Stewart, M., Bell, M., James, C., Evan, G., Neil, J. C., and Cameron, E. R. Oncogene 19, 773-82 (2000). |
|
|
Reversible activation of c-Myc in thymocytes enhances positive selection and induces proliferation and apoptosis in vitro. Rudolph, B., Hueber, A. O., and Evan, G. I. Oncogene 19, 1891-900 (2000). |
|
|
The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Lindsten, T., Ross, A. J., King, A., Zong, W. X., Rathmell, J. C., Shiels, H. A., Ulrich, E., Waymire, K. G., Mahar, P., Frauwirth, K., Chen, Y., Wei, M., Eng, V. M., Adelman, D. M., Simon, M. C., Ma, A., Golden, J. A., Evan, G., Korsmeyer, S. J., MacGregor, G. R., and Thompson, C. B. Mol Cell 6, 1389-99 (2000). |
|
|
A dominant negative Fas-associated death domain protein mutant inhibits proliferation and leads to impaired calcium mobilization in both T-cells and fibroblasts. Hueber, A. O., Zornig, M., Bernard, A. M., Chautan, M., and Evan, G. J Biol Chem 275, 10453-62. (2000). |
|
|
Proliferation, cell cycle and apoptosis in cancer. Evan, G. I., and Vousden, K. H. Nature 411, 342-8. (2001). |
|
|
Expression of Mad1 in T cells leads to reduced thymic cellularity and impaired mitogen-induced proliferation. Rudolph, B., Hueber, A. O., and Evan, G. I. Oncogene 20, 1164-75. (2001). |
|
|
Caspase-mediated cleavage of the Ca2+/calmodulin-dependent protein kinase-like kinase (CaMKLK) facilitates neuronal apoptosis. Kruidering, M., Schouten, T., Evan, G. I., and Vreugdenhil, E. J Biol Chem 30, 30 (2001). |
|
|
Suppression of Myc-inducted apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Pelengaris, S., Khan, M., and Evan, G. Cell 109,321-334. (2002). |
|
|
c-Myc functionally cooperates with Bax to induce apoptosis. Juin, P., Hunt, A., Littlewood, T., Griffiths, B., Brown-Swigart,L., Korsmeyer, S., Evan, G. Mol and Cellular Biol 22(17), 6158-6169. (2002). |
|
|
The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Verschuren, E.W, Klefstrom, J., Evan G. Cancer Cell, 2, 229-241(2002). |
|
|
c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway. Klefstrom, J., Verschuren, E.W., Evan G. J.Biol.Chem., 277, 43224-32 (2002) |
|
|
c-Myc induces cytochrome c release in Rat1 fibroblasts by increasing outer mitochondrial membrane permeability in a Bid-dependent manner. Iaccarino, I., D. Hancock, Evan, G. I., Downward, J. Cell Death Differ 10, 599-608. (2003). |
|
|
"Minimal BH3 Peptides Promote Cell Death by Antagonizing Anti-apoptotic Proteins." Moreau, C., Cartron, P.F., Hunt, A., Meflah, K., Green, D. R., Evan, G., Vallette, F. M., Juin, P. J Biol Chem 278:19426-35. (2003). |
|
|
c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Kanazawa, S., Soucek, L., Evan, G., Okamoto, T., and Peterlin, B. M. Oncogene 22, 5707-5711. (2003). |
|
|
Murphy, D.J. Brown Swigart, L., Israel, M.A. and Evan, G.I. (2004) Id2 is dispensable for Myc-induced epidermal hyperplasia. Mol Cell Biol. 24: 2083-2090. |
|
|
Verschuren, E. W., Hodgson, J. G., Gray, J. W., Kogan, S., Jones, N., and Evan, G. I. (2004). The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res 64, 581-589. |
|
|
Soucek, L., Nasi, S. Evan, G. I. (2004) Omomyc expression in skin prevents Myc-induced papillomatosis. Cell Death Diff. 11, 1038-45. |
|
|
Flores, I., Murphy, D.J., Brown Swigart, L., Knies, U. and Evan, G.I. (2004). Exploiting inherent differentiation to counteract c-Myc-driven keratinocyte proliferation in vivo. Oncogene 23, 5923-30. |
|
|
Vyas, S., Juin, P., Hancock, D. C., Suzuki, Y., Takahashi, R., Triller, A. and Evan, G. I. (2004) Differentiation dependent sensitivity to apoptogenic factors in PC12 cells. J Biol Chem 279, 30983-93. |
|
|
Knies-Bamforth, U. E., Fox, S. B., Poulsom, R., Evan, G. I. and Harris, A. L. (2004) c-Myc interacts with hypoxia to induce angiogenesis in vivo by a VEGF-dependent mechanism. Cancer Res 64, 6583-70. |
|
|
Broaddus, V. C., Dansen, T. B., Abayasiriwardana, K. S., Finch, A. J., Swigart, L. B. Hunt, A. E. and Evan, G. I. Bid Mediates Apoptotic Synergy Between TNF-related Apoptosis-inducing Ligand (TRAIL) and DNA Damage. J Biol Chem 280, 12486-93 |
|
|
Lowe, S. W., Cepero, E., and Evan, G. (2004). Intrinsic tumour suppression. Nature 432, 307-315. |
|
|
Christophorou, M., Martin-Zanca, D., Soucek, L. Lawlor, E.R., Brown-Swigart, L., Vershuren, E. and Evan, G. I. (2005) Temporal dissection of p53 function in vitro and in vivo. Nature GeneticsE-pub May 2005 |
|
|
Dansen, T. B., Whitfield, J., Rostker, F., Brown-Swigart, L., and Evan, G. I. (2006). Specific requirement for Bax, not Bak, in MYC-induced apoptosis and tumor suppression in vivo. J Biol Chem. 281, 10890-95. |
|
|
Lawlor, E. R., Soucek, L., Brown-Swigart, L., Shchors, K., Bialucha, C. U., and Evan, G. I. (2006). Reversible Kinetic Analysis of Myc Targets In vivo Provides Novel Insights into Myc-Mediated Tumorigenesis. Cancer Res 66. 4591-601. |
|
|
Jelluma, N., Yang, X., Stokoe, D., Evan, G., Dansen, T., and Haas-Kogan, D. (2006). Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res 4: 319-330. |
|
|
Christophorou, M.A., Ringshausen I., Finch A.J., Brown Swigart L. and Evan, G.I. (2006) The pathological p53-mediated response to DNA damage is distinct from p53-mediated tumor suppression. Nature. 443(7108):214-7. Sep 6. |
|
|
Shchors K, Shchors E, Rostker F, Lawlor ER, Brown-Swigart L, Evan GI. (2006) The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1b. Genes Dev. 20(18):2527-38. |
|
|
Finch A, Prescott J, Shchors K, Hunt A, Soucek L, Dansen TB, Swigart LB, Evan GI. (2006) Bcl-xL gain of function and p19ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms. Cancer Cell. Aug;10(2):113-20. |
|
|
Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. (2006) Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Cancer Cell. Dec;10(6):501-14. |
|
|
Martins CP, Brown-Swigart L, Evan GI. (2006) Modeling the Therapeutic Efficacy of p53 Restoration in Tumors. Cell. Dec 29;127(7):1323-34. | |
|
7/13/07 |
|
